Ahmed Glaucoma Valve Alone, With Amniotic Membrane or With Mitomycin C (MMC) for Treatment of Refractory Glaucoma
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This randomized, controlled trial (RCT) compares the efficacy and safety of Ahmed Glaucoma
Valve (AGV) implantation alone, with 3 minutes MMC application or with a single layer
coverage of amniotic membrane. Outcomes include intraocular eye pressure (IOP), postoperative
glaucoma medication and complications. AGV implantation site will be superior or inferior
based on indication and these groups will be randomized separately.